Our new search engine has been lanuched. Welcome to use it and experience it. If you have any suggestions, welcome to contact us!
Text SizeAAA

Management Team

  • Dr. Daniel I.C. Wang
  • Chairman of the Scientific Advisory Board
  • Institute Professor from MIT
  • Member of National Academy of Engineering,
  • American Academy of Arts and Sciences, and Academia Sinica

Dr. Daniel I.C. Wang is an Institute Professor at Massachusetts Institute of Technology and Termasek Professor at the National University of Singapore. He is a member of National Academy of Engineering, American Academy of Arts and Sciences, Academia Sinica, American Institute of Medical and Biological Engineering, and International Institute of Biotechnology. He received his MS degree from MIT, and Ph.D. from University of Pennsylvania. He also received honorary doctorates from Hong Kong University of Science and technology, the Catholic University Valparaiso, Chile, and Honorary Professorships from Peking Union Medical College, China, and Zhejiang University, China. Dr. Wang also won numerous prestigious awards including the Amgen Award from the Engineering Foundation, Food, Pharmaceutical and Bioengineering Award and William H. Walker Award from AICHE.

Over 40 years of pioneering and innovative research in the field of biotechnology and biochemical engineering, Prof. Wang has made profound impact on the biotechnology industry scientific research, and education. He founded and directed the NSF funded Biotechnology Process Engineering Center for more than 10 years. He was the editor-in-chief for Biotechnology and Bioengineering for more than 10 years. He resides and has resided as editorial board members for 8 scientific journals. His research interests and contribution to the biotech industry include mammalian cell culture, microbial fermentation, protein purification and refolding, bioreactor engineering, production of recombinant proteins, bioprocess monitoring and control, glycoprotein quality, protein stabilization, enzyme technology, and cellulosic Biomass conversion. He has authored 5 books, over 230 research publications, and 15 patents. He has consulted for over 50 companies worldwide and was on the board of directors and scientific advisory boards on a number of public and private companies.

Liangzhi Xie
  • Dr. Liangzhi Xie
  • President and CEO
  • MIT Ph.D.
  • Former Research Fellow from Merck & Company

Dr. Xie obtained his doctor degree from the Biotechnology Process Engineering Center at Massachusetts Institute of Technology under the supervision of Prof. Daniel I.C. Wang. At MIT, Dr. Xie developed a stoichiometric model to optimize the design of mammalian cell culture medium and the control of the dynamic culture environment. In 1994, he was able to achieve a record cell density of 1.7 x 107 cells/ml and a record antibody titer of 2.4 gram/L. He then worked on viral vaccine process development and cGMP manufacturing for three US FDA approved products (Varicella® , Zostervax® , and ProQuad® ) at Merck Research Laboratory, Merck & Company. He also led the cell culture and viral vaccine process development and cGMP clinical production for Merck’s adenovirus based HIV vaccine and helped to develop by far the largest scale (2000L) of human viral vaccine process under serum-free condition in stirred-tank bioreactors. He is also the director and professor at the Cell Culture R&D center at the Peking Union Medical College since 2002.

Key Facts
  • 300+
  • Scientists/Engineers
  • 30+
  • PhDs
  • 70+
  • Countries delivered to worldwide
  • 7000+
  • Labs delivered to worldwide
  • Top 10
  • Pharm corporations served
  • 10˜160
  • Antibody improvement comparing with other brand